Medical Practice Partnership Buy-In Guide: What Physicians Need to Know Before Signing (2026)

This guide explains how physician practice buy-ins actually work — how practices are valued, what a fair buy-in looks like across specialties, what structures are used to structure the payment, what ownership actually entitles you to, and the specific terms every physician must review before signing. Whether you are being offered partnership at a private practice, a multispecialty group, or a specialty-specific partnership in a high-value specialty, the framework here applies.

What Is a Medical Practice Buy-In and What Does It Actually Buy You?

A medical practice buy-in is the purchase of an ownership interest — equity — in an existing medical practice. When you buy in, you transition from employee to owner. That transition has clinical, operational, and financial dimensions that salary comparison alone cannot capture.

How Medical Practices Are Valued

The buy-in price is derived from the practice valuation. If you are purchasing 20 percent ownership in a practice valued at $1 million, your buy-in is $200,000. Understanding how the practice arrived at its stated value is essential before agreeing to pay.

Method 1: EBITDA Multiple (The Institutional Standard)

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization — a proxy for the cash a practice generates before accounting for how it is financed and how the owner takes money out.

Medical practices typically sell for EBITDA multiples ranging from 6x to 12x. Primary care typically falls in the 3–6x EBITDA range while specialties reach 6–11x. For physician-to-physician partnership buy-ins, EBITDA multiples are typically lower (3x to 6x) than those in third-party private equity transactions.

The normalization step is critical and frequently disputed. This is why an independent accountant reviewing the numbers before you sign is not optional.

Method 2: Revenue Multiple (Collections Approach)

Simpler but less precise. The practice's annual net collections are multiplied by a percentage to arrive at value. Smaller practices often use 40 to 70 percent of collections as a rough valuation benchmark. Revenue multiples are most useful for quick sanity checks and for practices where EBITDA is thin or volatile.

The significant weakness: Two practices with identical collections can have dramatically different profitability. A $5M cardiology practice with 25% margins is worth far more than a $5M practice with 8% margins. Revenue multiples ignore this reality.

Method 3: Asset-Based Valuation

The practice's tangible assets — equipment, receivables, furniture, real estate if owned — are valued and summed. Less common for ongoing practice buy-ins because it ignores the going-concern value of patient relationships, referral networks, staff, payer contracts, and established cash flow.

Goodwill: Personal vs. Practice — Understanding the Distinction

Goodwill is the value of a medical practice above and beyond its tangible assets — representing patient loyalty, reputation, established referral relationships, payer contracts, brand recognition, and systems. This is where buy-in valuations most commonly generate disputes.

• •Personal goodwill is goodwill attributable to a specific physician's reputation, skills, and relationships — goodwill that follows that physician rather than remaining with the practice.
• •Practice goodwill is goodwill attributable to the practice entity itself — location, staff quality, established patient panel, payer contracts, facility, and systems — goodwill that remains when any individual physician leaves.

In a physician-to-physician buy-in, you should be paying for practice goodwill, not personal goodwill. Asking you to pay for personal goodwill is asking you to pay for something that may evaporate if that physician leaves or reduces their role.

Specialty-Level Buy-In Expectations in 2026

Buy-in amounts vary dramatically by specialty based on practice profitability, ASC ownership value, ancillary service revenue, and local market dynamics. Here are general ranges for physician-to-physician partnership buy-ins in 2026 for a 10% to 33% stake:

The ASC Ownership Buy-In: Where the Real Value Lives

For surgical specialties, the most financially significant component of a partnership buy-in is frequently not the practice itself but the associated ambulatory surgery center (ASC) ownership. As discussed in our Orthopedic Surgery Salary guide, a surgeon with a 20% ownership stake in a high-volume ASC can receive $500,000 to $1.2 million annually in facility distributions on top of their clinical salary.

When evaluating a partnership offer that includes ASC ownership, always analyze the ASC's financial performance separately from the practice. Key metrics to review:

• 1.ASC EBITDA and operating margin: A well-run orthopedic ASC should generate EBITDA margins of 25 to 40 percent.
• 2.Payer mix: An ASC with a predominantly commercial payer mix generates dramatically more per-case revenue than one dependent on Medicare.
• 3.Case volume trends: Is surgical volume growing, stable, or declining?
• 4.Ownership structure: What happens to your ownership if you retire, become disabled, or choose to leave the group?

Buy-In Structures: How the Payment Is Made

The mechanics of how you pay the buy-in amount matter significantly for your cash flow and tax situation.

Installment Purchase

The most common structure. You pay the buy-in amount over a defined period (typically 3 to 7 years) from your increased partner income. The critical question: Does your expected income increase exceed the annual installment payment by enough to justify the financial and administrative obligations of ownership?

Lump Sum Payment

Common in higher-value specialty practices and ASC equity transactions. Physicians frequently use practice loans to fund a lump sum buy-in. A $300,000 buy-in loan at 8% over 7 years pays approximately $4,700 per month in loan service.

Sweat Equity / Earned Equity

The practice credits a portion of the economic value you generated as an associate against the buy-in price. Important to understand exactly how the earned equity is calculated and documented to avoid vague promises.

What You Must Evaluate Before Signing

How to Calculate Whether a Buy-In Is Worth It

A simple but effective framework uses the payback period — how many years it takes to recover the buy-in investment through incremental distributions:

Example: A gastroenterologist is offered partnership for a buy-in of $350,000. As an employee, they earn $520,000 per year. As a partner, they project distributions of $190,000 annually above their clinical salary. Annual income increase: $190,000. Payback period: $350,000 ÷ $190,000 = 1.8 years.

A payback period under 3 years is generally considered favorable. 3 to 5 years is acceptable. Beyond 5 years warrants careful scrutiny.

The Private Equity Context: How PE Changes the Buy-In Calculus

Private equity remains the dominant buyer in physician practice M&A. For physicians evaluating a partnership buy-in at a practice that is either already PE-backed or likely to attract PE interest, the calculus differs:

• •If the practice is already PE-backed: You are buying a minority interest where a PE firm controls the majority. Governance rights are limited. The timeline to a "liquidity event" is typically 5 to 7 years. At that event, physician equity holders receive their proportional share of the purchase price — potentially a significant multiple of their buy-in investment.
• •If the practice is a likely PE acquisition target: Buying into a thriving private practice that subsequently gets acquired by PE can produce a significant windfall. A physician who buys 10% of a specialty practice for $400,000 and whose practice is acquired at an 8x EBITDA multiple may receive $1.5M to $3M. This potential upside explains why well-positioned specialty practices command higher buy-in prices in 2026.

The Professional Team You Need for Any Buy-In

Do not attempt to evaluate or negotiate a medical practice buy-in without professional representation. Without independent review, you are making one of the largest financial decisions of your career without objective analysis.

• •Healthcare attorney ($3,000 to $8,000): Reviews the partnership agreement, identifies unfavorable terms, negotiates modifications. Essential.
• •CPA with medical practice experience ($2,000 to $5,000): Reviews the practice financial statements, validates the EBITDA normalization, assesses the valuation methodology. Essential.
• •Independent valuator: For buy-ins above $500,000, an independent practice valuation from an ASA or ABV-certified appraiser provides an objective fair market value opinion.

For a comparison of financial advisors who specialize in physician practice transactions, see our financial advisors review page.

Red Flags That Warrant Serious Scrutiny

• ⚠️The buy-in price is calculated on collections, not EBITDA. A practice with 10% operating margins valued at 70% of collections is selling for 7x EBITDA — very rich for a physician-to-physician buy-in.
• ⚠️No audited or reviewed financial statements are available. Relying on internally generated spreadsheets creates opportunities for selective reporting.
• ⚠️The buy-in creates no meaningful governance rights. Buying a 10% stake where a majority partner controls all decisions is buying a minority position with little practical influence.
• ⚠️The non-compete is broader than the practice's actual service area.
• ⚠️The practice is acquiring new partners every 1 to 3 years. Frequent partner turnover signals governance disputes, distribution disagreements, or clinical culture problems.